Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
In Vitro DiagnosticsCancerCancer Diagnostic

PUBLISHER: Data Bridge Market Research | PRODUCT CODE: 1223493

Cover Image

PUBLISHER: Data Bridge Market Research | PRODUCT CODE: 1223493

MEA Uterine Cancer Diagnostics Market - Industry Trends and Forecast to 2030

PUBLISHED:
PAGES: 403 Pages
DELIVERY TIME: Inquiry
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF (Single User License) - Printable/Downloadable
USD 3500
PDF (Enterprise License) - Printable/Downloadable
USD 4200

Add to Cart

Description

Table of Contents

List of Tables

The Middle East and Africa uterine cancer diagnostics market is projected to register a CAGR of 8.5% in the forecast period of 2023 to 2030. The new market report contains data for the historic year 2021, the base year of calculation is 2022, and the forecast period is 2023 to 2030.

Market Segmentation:

Middle East and Africa Uterine Cancer Diagnostics Market, By Diagnostic Type (Instrument Based and Procedure Based), Type (Endometrial Cancer and Uterine Sarcoma), Age Group (<30, 31-40, 41-50, 51-60 And >60), End User (Hospitals, Diagnostic Centres, Cancer Research Centre, Ambulatory Surgical Centres, Specialized Clinics, and Others), Distribution Channel (Direct Tender, Third Party Distributors, and Others), Country (South Africa, Saudi Arabia, UAE, Egypt, Israel, the Rest of the Middle East and Africa) Industry Trends and Forecast to 2030.

Some of the major factors contributing to the growth of the Global uterine cancer diagnostics market are:

Increasing uterine cancer patients among the women population

Rise in technological advancement for uterine cancer diagnosis

Market Players

Some of the key market players operating in the Middle East and Africa uterine cancer diagnostics market are:

Siemens Healthcare Private Limited

Olympus Corporation

Integra LifeSciences

KARL STORZ SE & Co. KG

Stryker

General Electric Company

FUJIFILM Corporation

Koninklijke Philips N.V.

B. Braun SE

Medtronic

Show more

TABLE OF CONTENTS

1 INTRODUCTION 117

  • 1.1 OBJECTIVES OF THE STUDY 117
  • 1.2 MARKET DEFINITION 117
  • 1.3 OVERVIEW OF THE MIDDLE EAST & AFRICA UTERINE CANCER DIAGNOSTIC MARKET 117
  • 1.4 CURRENCY AND PRICING 119
  • 1.5 LIMITATIONS 119
  • 1.6 MARKETS COVERED 119

2 MARKET SEGMENTATION 127

  • 2.1 MARKETS COVERED 127
  • 2.2 GEOGRAPHICAL SCOPE 128
  • 2.3 YEARS CONSIDERED FOR THE STUDY 129
  • 2.4 DBMR TRIPOD DATA VALIDATION MODEL 130
  • 2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 133
  • 2.6 MULTIVARIATE MODELLING 134
  • 2.7 MARKET APPLICATION COVERAGE GRID 135
  • 2.8 INSTRUMENT BASED LIFELINE CURVE 136
  • 2.9 DBMR MARKET POSITION GRID 137
  • 2.10 VENDOR SHARE ANALYSIS 139
  • 2.11 SECONDARY SOURCES 140
  • 2.12 ASSUMPTIONS 140

3 EXECUTIVE SUMMARY 141

4 PREMIUM INSIGHTS 144

  • 4.1 PESTEL ANALYSIS 145
  • 4.2 PORTER'S FIVE FORCES 146
  • 4.3 PATENT ANALYSIS OF MIDDLE EAST & AFRICA UTERINE CANCER DIAGNOSTICS MARKET 147
  • 4.4 REIMBURSEMENT SCENARIO 148
  • 4.5 INDUSTRY INSIGHTS: 149
  • 4.6 DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATES 149
  • 4.7 PRICING STRATEGIES 149
  • 4.8 CONCLUSION 150
  • 4.9 PREVALENCE, INCIDENCE, AND MORTALITY RATE OF UTERINE CANCER 151
  • 4.10 COST OF UTERINE CANCER PROCEDURE 153

5 REGULATORY FRAMEWORK 154

6 MARKET OVERVIEW 156

  • 6.1 DRIVERS 158
    • 6.1.1 TECHNOLOGICAL ADVANCEMENTS IN UTERINE CANCER DIAGNOSTICS 158
    • 6.1.2 RISING DEMAND FOR MINIMALLY INVASIVE ADVANCED SCREENING TECHNIQUES 158
    • 6.1.3 RISING AWARENESS TOWARDS UTERINE CANCER 159
    • 6.1.4 RISING IMPORTANCE OF WOMEN'S HEALTH 159
  • 6.2 RESTRAINTS 160
    • 6.2.1 HIGH RISK COMPLICATIONS DURING DIAGNOSTIC TESTS 160
    • 6.2.2 LACK OF SKILLED PROFESSIONALS FOR PROPER DIAGNOSIS OF UTERINE CANCER 160
  • 6.3 OPPORTUNITIES 161
    • 6.3.1 INCREASING PREVALENCE OF UTERINE CANCER 161
    • 6.3.2 RISE IN ADOPTION OF SEDENTARY LIFESTYLE 161
    • 6.3.3 GROWTH IN MENSTRUAL COMPLICATIONS 162
  • 6.4 CHALLENGES 162
    • 6.4.1 LACK OF DIAGNOSTIC INFRASTRUCTURE 162
    • 6.4.2 HIGH COST OF IMAGING SYSTEMS 163

7 MIDDLE EAST & AFRICA UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE 164

  • 7.1 OVERVIEW 165
  • 7.2 INSTRUMENT-BASED 168
    • 7.2.1 ULTRASOUND SCANNING 169
      • 7.2.1.1 SYSTEMS 169
      • 7.2.1.2 ABDOMINAL ULTRASOUND SCANNING 170
      • 7.2.1.3 TRANSVAGINAL ULTRASOUND SCANNING 170
      • 7.2.1.4 ACCESSORIES 170
    • 7.2.2 IMAGING DEVICES 170
      • 7.2.2.1 CT/PET (POSITRON EMISSION TOMOGRAPHY) SCAN 171
      • 7.2.2.2 MAGNETIC RESONANCE IMAGING (MRI) 171
      • 7.2.2.3 COMPUTED TOMOGRAPHY (CT) SCAN 171
      • 7.2.2.4 OTHERS 171
    • 7.2.3 TESTS 172
      • 7.2.3.1 BLOOD TESTS 172
        • 7.2.3.1.1 COMPLETE BLOOD COUNT 172
        • 7.2.3.1.2 CA125 MARKER BLOOD TEST 172
      • 7.2.3.2 URINE TESTS 173
      • 7.2.3.3 OTHER TESTS 173
    • 7.2.4 OTHERS 173
  • 7.3 PROCEDURE BASED 173
    • 7.3.1 ENDOMETRIAL BIOPSY 174
    • 7.3.2 HYSTEROSCOPY 174
    • 7.3.3 DILATION & CURETTAGE 174
    • 7.3.4 CYSTOSCOPY 174
    • 7.3.5 PROCTOSCOPY 175
    • 7.3.6 OTHERS 175

8 MIDDLE EAST & AFRICA UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE 176

  • 8.1 OVERVIEW 177
  • 8.2 ENDOMETRIAL CANCER 180
    • 8.2.1 SEROUS ADENOCARCINOMA 181
      • 8.2.1.1 INSTRUMENT-BASED 181
        • 8.2.1.1.1 ULTRASOUND SCANNING 182
        • 8.2.1.1.2 IMAGING DEVICES 182
        • 8.2.1.1.3 TESTS 182
        • 8.2.1.1.4 OTHERS 182
      • 8.2.1.2 PROCEDURE-BASED 183
        • 8.2.1.2.1 ENDOMETRIAL BIOPSY 183
        • 8.2.1.2.2 HYSTEROSCOPY 183
        • 8.2.1.2.3 DILATION & CURETTAGE 183
        • 8.2.1.2.4 CYSTOSCOPY 183
        • 8.2.1.2.5 PROCTOSCOPY 183
        • 8.2.1.2.6 OTHERS 184
    • 8.2.2 ADENOSQUAMOUS CARCINOMA 184
      • 8.2.2.1 INSTRUMENT-BASED 184
        • 8.2.2.1.1 ULTRASOUND SCANNING 184
        • 8.2.2.1.2 IMAGING DEVICES 185
        • 8.2.2.1.3 TESTS 185
        • 8.2.2.1.4 OTHERS 185
      • 8.2.2.2 PROCEDURE-BASED 185
        • 8.2.2.2.1 ENDOMETRIAL BIOPSY 185
        • 8.2.2.2.2 HYSTEROSCOPY 185
        • 8.2.2.2.3 DILATION & CURETTAGE 186
        • 8.2.2.2.4 CYSTOSCOPY 186
        • 8.2.2.2.5 PROCTOSCOPY 186
        • 8.2.2.2.6 OTHERS 186
    • 8.2.3 UTERINE CARCINOSARCOMA 186
      • 8.2.3.1 INSTRUMENT-BASED 186
        • 8.2.3.1.1 ULTRASOUND SCANNING 187
        • 8.2.3.1.2 IMAGING DEVICES 187
        • 8.2.3.1.3 TESTS 187
        • 8.2.3.1.4 OTHERS 187
      • 8.2.3.2 PROCEDURE-BASED 188
        • 8.2.3.2.1 ENDOMETRIAL BIOPSY 188
        • 8.2.3.2.2 HYSTEROSCOPY 188
        • 8.2.3.2.3 DILATION & CURETTAGE 188
        • 8.2.3.2.4 CYSTOSCOPY 188
        • 8.2.3.2.5 PROCTOSCOPY 188
        • 8.2.3.2.6 OTHERS 189
    • 8.2.4 PRIMARY PURE SQUAMOUS CELL CARCINOMA OF THE ENDOMETRIUM 189
      • 8.2.4.1 INSTRUMENT-BASED 189
        • 8.2.4.1.1 ULTRASOUND SCANNING 189
        • 8.2.4.1.2 IMAGING DEVICES 190
        • 8.2.4.1.3 TESTS 190
        • 8.2.4.1.4 OTHERS 190
      • 8.2.4.2 PROCEDURE-BASED 190
        • 8.2.4.2.1 ENDOMETRIAL BIOPSY 190
        • 8.2.4.2.2 HYSTEROSCOPY 190
        • 8.2.4.2.3 DILATION & CURETTAGE 191
        • 8.2.4.2.4 CYSTOSCOPY 191
        • 8.2.4.2.5 PROCTOSCOPY 191
        • 8.2.4.2.6 OTHERS 191
  • 8.3 UTERINE SARCOMA 191
    • 8.3.1 LEIOMYOSARCOMA 192
      • 8.3.1.1 INSTRUMENT-BASED 192
        • 8.3.1.1.1 ULTRASOUND SCANNING 193
        • 8.3.1.1.2 IMAGING DEVICES 193
        • 8.3.1.1.3 TESTS 193
        • 8.3.1.1.4 OTHERS 193
      • 8.3.1.2 PROCEDURE-BASED 194
        • 8.3.1.2.1 ENDOMETRIAL BIOPSY 194
        • 8.3.1.2.2 HYSTEROSCOPY 194
        • 8.3.1.2.3 DILATION & CURETTAGE 194
        • 8.3.1.2.4 CYSTOSCOPY 194
        • 8.3.1.2.5 PROCTOSCOPY 194
        • 8.3.1.2.6 OTHERS 195
    • 8.3.2 ENDOMETRIAL STROMAL SARCOMA 195
      • 8.3.2.1 INSTRUMENT-BASED 195
        • 8.3.2.1.1 ULTRASOUND SCANNING 195
        • 8.3.2.1.2 IMAGING DEVICES 196
        • 8.3.2.1.3 TESTS 196
        • 8.3.2.1.4 OTHERS 196
      • 8.3.2.2 PROCEDURE-BASED 196
        • 8.3.2.2.1 ENDOMETRIAL BIOPSY 196
        • 8.3.2.2.2 HYSTEROSCOPY 196
        • 8.3.2.2.3 DILATION & CURETTAGE 197
        • 8.3.2.2.4 CYSTOSCOPY 197
        • 8.3.2.2.5 PROCTOSCOPY 197
        • 8.3.2.2.6 OTHERS 197
    • 8.3.3 UNDIFFERENTIATED SARCOMA 197
      • 8.3.3.1 INSTRUMENT-BASED 198
        • 8.3.3.1.1 ULTRASOUND SCANNING 198
        • 8.3.3.1.2 IMAGING DEVICES 198
        • 8.3.3.1.3 TESTS 198
        • 8.3.3.1.4 OTHERS 198
      • 8.3.3.2 PROCEDURE-BASED 199
        • 8.3.3.2.1 ENDOMETRIAL BIOPSY 199
        • 8.3.3.2.2 HYSTEROSCOPY 199
        • 8.3.3.2.3 DILATION & CURETTAGE 199
        • 8.3.3.2.4 CYSTOSCOPY 199
        • 8.3.3.2.5 PROCTOSCOPY 200
        • 8.3.3.2.6 OTHERS 200

9 MIDDLE EAST & AFRICA UTERINE CANCER DIAGNOSTICS MARKET, BY AGE GROUP 201

  • 9.1 OVERVIEW 202
  • 9.2 >60 YEARS 205
  • 9.3 51-60 YEARS 206
  • 9.4 41-50 YEARS 207
  • 9.5 31-40 YEARS 208
  • 9.6 <30 YEARS 209

10 MIDDLE EAST & AFRICA UTERINE CANCER DIAGNOSTICS MARKET, BY END USER 210

  • 10.1 OVERVIEW 211
  • 10.2 HOSPITALS 214
  • 10.3 DIAGNOSTIC CENTERS 215
  • 10.4 CANCER RESEARCH CENTERS 216
  • 10.5 AMBULATORY SURGICAL CENTERS 217
  • 10.6 SPECIALIZED CLINICS 218
  • 10.7 OTHERS 219

11 MIDDLE EAST & AFRICA UTERINE CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL 220

  • 11.1 OVERVIEW 221
  • 11.2 DIRECT TENDER 224
  • 11.3 THIRD PARTY DISTRIBUTORS 225
  • 11.4 OTHERS 226

12 MIDDLE EAST & AFRICA UTERINE CANCER DIAGNOSTICS MARKET, BY REGION 227

  • 12.1 MIDDLE EAST AND AFRICA 228
    • 12.1.1 SOUTH AFRICA 245
    • 12.1.2 SAUDI ARABIA 258
    • 12.1.3 BAHRAIN 271
    • 12.1.4 UAE 284
    • 12.1.5 EGYPT 296
    • 12.1.6 ISRAEL 309
    • 12.1.7 KUWAIT 322
    • 12.1.8 OMAN 335
    • 12.1.9 QATAR 348
    • 12.1.10 REST OF MIDDLE EAST AND AFRICA 361

13 MIDDLE EAST & AFRICA UTERINE CANCER DIAGNOSTICS MARKET, COMPANY LANDSCAPE 362

  • 13.1 COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA 362

14 SWOT ANALYSIS 363

15 COMPANY PROFILE 364

  • 15.1 KONINKLIJKE PHILIPS N.V. 364
    • 15.1.1 COMPANY SNAPSHOT 364
    • 15.1.2 REVENUE ANALYSIS 364
    • 15.1.3 COMPANY SHARE ANALYSIS 365
    • 15.1.4 PRODUCT PORTFOLIO 365
    • 15.1.5 RECENT DEVELOPMENTS 365
  • 15.2 CANON MEDICAL SYSTEMS ANZ PTY LIMITED. 367
    • 15.2.1 COMPANY SNAPSHOT 367
    • 15.2.2 COMPANY SHARE ANALYSIS 367
    • 15.2.3 PRODUCT PORTFOLIO 368
    • 15.2.4 RECENT DEVELOPMENTS 368
  • 15.3 GENERAL ELECTRIC COMPANY 369
    • 15.3.1 COMPANY SNAPSHOT 369
    • 15.3.2 REVENUE ANALYSIS 369
    • 15.3.3 COMPANY SHARE ANALYSIS 370
    • 15.3.4 PRODUCT PORTFOLIO 370
    • 15.3.5 RECENT DEVELOPMENTS 370
  • 15.4 SIEMENS HEALTHCARE GMBH 372
    • 15.4.1 COMPANY SNAPSHOT 372
    • 15.4.2 REVENUE ANALYSIS 372
    • 15.4.3 COMPANY SHARE ANALYSIS 373
    • 15.4.4 PRODUCT PORTFOLIO 373
    • 15.4.5 RECENT DEVELOPMENTS 373
  • 15.5 FUJIFILM CORPORATION 374
    • 15.5.1 COMPANY SNAPSHOT 374
    • 15.5.2 REVENUE ANALYSIS 374
    • 15.5.3 COMPANY SHARE ANALYSIS 375
    • 15.5.4 PRODUCT PORTFOLIO 375
    • 15.5.5 RECENT DEVELOPMENTS 375
  • 15.6 AED.MD 377
    • 15.6.1 COMPANY SNAPSHOT 377
    • 15.6.2 PRODUCT PORTFOLIO 377
    • 15.6.3 RECENT DEVELOPMENTS 377
  • 15.7 ARQUER DIAGNOSTICS LTD 378
    • 15.7.1 COMPANY SNAPSHOT 378
    • 15.7.2 PRODUCT PORTFOLIO 378
    • 15.7.3 RECENT DEVELOPMENTS 378
  • 15.8 B. BRAUN SE 379
    • 15.8.1 COMPANY SNAPSHOT 379
    • 15.8.2 PRODUCT PORTFOLIO 379
    • 15.8.3 RECENT DEVELOPMENTS 379
  • 15.9 ESAOTE SPA 380
    • 15.9.1 COMPANY SNAPSHOT 380
    • 15.9.2 PRODUCT PORTFOLIO 380
    • 15.9.3 RECENT DEVELOPMENTS 380
Show more
  • 15.10 F. HOFFMANN-LA ROCHE LTD 382
    • 15.10.1 COMPANY SNAPSHOT 382
    • 15.10.2 REVENUE ANALYSIS 382
    • 15.10.3 PRODUCT PORTFOLIO 383
    • 15.10.4 RECENT DEVELOPMENTS 383
  • 15.11 GRAIL 384
    • 15.11.1 COMPANY SNAPSHOT 384
    • 15.11.2 PRODUCT PORTFOLIO 384
    • 15.11.3 RECENT DEVELOPMENTS 384
  • 15.12 GUZIP BIOMARKERS CORPORATION 386
    • 15.12.1 COMPANY SNAPSHOT 386
    • 15.12.2 PRODUCT PORTFOLIO 386
    • 15.12.3 RECENT DEVELOPMENTS 386
  • 15.13 INTEGRA LIFESCIENCES 387
    • 15.13.1 COMPANY SNAPSHOT 387
    • 15.13.2 REVENUE ANALYSIS 387
    • 15.13.3 PRODUCT PORTFOLIO 388
    • 15.13.4 RECENT DEVELOPMENTS 388
  • 15.14 JALAL SURGICAL 389
    • 15.14.1 COMPANY SNAPSHOT 389
    • 15.14.2 PRODUCT PORTFOLIO 389
    • 15.14.3 RECENT DEVELOPMENTS 389
  • 15.15 KARL STORZ SE & CO. KG 390
    • 15.15.1 COMPANY SNAPSHOT 390
    • 15.15.2 PRODUCT PORTFOLIO 390
    • 15.15.3 RECENT DEVELOPMENTS 391
  • 15.16 MEDTRONIC 392
    • 15.16.1 COMPANY SNAPSHOT 392
    • 15.16.2 REVENUE ANALYSIS 392
    • 15.16.3 PRODUCT PORTFOLIO 393
    • 15.16.4 RECENT DEVELOPMENTS 393
  • 15.17 NARANG MEDICAL LIMITED 394
    • 15.17.1 COMPANY SNAPSHOT 394
    • 15.17.2 PRODUCT PORTFOLIO 394
    • 15.17.3 RECENT DEVELOPMENTS 394
  • 15.18 OLYMPUS CORPORATION 395
    • 15.18.1 COMPANY SNAPSHOT 395
    • 15.18.2 REVENUE ANALYSIS 395
    • 15.18.3 PRODUCT PORTFOLIO 396
    • 15.18.4 RECENT DEVELOPMENTS 396
  • 15.19 STRYKER 397
    • 15.19.1 COMPANY SNAPSHOT 397
    • 15.19.2 REVENUE ANALYSIS 397
    • 15.19.3 PRODUCT PORTFOLIO 398
    • 15.19.4 RECENT DEVELOPMENTS 398
  • 15.20 SURTEX INSTRUMENTS LIMITED. 399
    • 15.20.1 COMPANY SNAPSHOT 399
    • 15.20.2 PRODUCT PORTFOLIO 399
    • 15.20.3 RECENT DEVELOPMENTS 399

16 QUESTIONNAIRE 400

17 RELATED REPORTS 403

LIST OF TABLES

  • TABLE 1 MIDDLE EAST & AFRICA RATE OF ENDOMETRIAL CANCER (2020) 73
  • TABLE 2 U.S. (2022) 73
  • TABLE 3 U.K. (2019) 73
  • TABLE 4 GERMANY RATE OF ENDOMETRIAL CANCER (2019) 73
  • TABLE 5 POLAND RATE OF ENDOMETRIAL CANCER (2020) 73
  • TABLE 6 SINGAPORE (2020) 73
  • TABLE 7 JAPAN (2022) 73
  • TABLE 8 INDIA (2020) 74
  • TABLE 9 AUSTRALIA (2022) 74
  • TABLE 10 BRAZIL RATE OF ENDOMETRIAL CANCER (2018) 74
  • TABLE 11 ARGENTINA (2020) 74
  • TABLE 12 UAE (2020) 74
  • TABLE 13 MIDDLE EAST & AFRICA UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 89
  • TABLE 14 MIDDLE EAST & AFRICA INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 90
  • TABLE 15 MIDDLE EAST & AFRICA INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 90
  • TABLE 16 MIDDLE EAST & AFRICA ULTRASOUND SCANNING IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 91
  • TABLE 17 MIDDLE EAST & AFRICA ULTRASOUND SCANNING IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (UNITS) 91
  • TABLE 18 MIDDLE EAST & AFRICA SYSTEMS IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 91
  • TABLE 19 MIDDLE EAST & AFRICA SYSTEMS IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (UNITS) 92
  • TABLE 20 MIDDLE EAST & AFRICA IMAGING DEVICES IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 92
  • TABLE 21 MIDDLE EAST & AFRICA IMAGING DEVICES IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (UNITS) 93
  • TABLE 22 MIDDLE EAST & AFRICA TESTS IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 94
  • TABLE 23 MIDDLE EAST & AFRICA BLOOD TESTS IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 94
  • TABLE 24 MIDDLE EAST & AFRICA PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 95
  • TABLE 25 MIDDLE EAST & AFRICA PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 96
  • TABLE 26 MIDDLE EAST & AFRICA PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (UNITS) 96
  • TABLE 27 MIDDLE EAST & AFRICA UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 101
  • TABLE 28 MIDDLE EAST & AFRICA ENDOMETRIAL CANCER IN UTERINE CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 102
  • TABLE 29 MIDDLE EAST & AFRICA ENDOMETRIAL CANCER IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 103
  • TABLE 30 MIDDLE EAST & AFRICA SEROUS ADENOCARCINOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 103
  • TABLE 31 MIDDLE EAST & AFRICA INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 104
  • TABLE 32 MIDDLE EAST & AFRICA PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 105
  • TABLE 33 MIDDLE EAST & AFRICA ADENOSQUAMOUS CARCINOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 106
  • TABLE 34 MIDDLE EAST & AFRICA INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 106
  • TABLE 35 MIDDLE EAST & AFRICA PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 107
  • TABLE 36 MIDDLE EAST & AFRICA UTERINE CARCINOSARCOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 108
  • TABLE 37 MIDDLE EAST & AFRICA INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 109
  • TABLE 38 MIDDLE EAST & AFRICA PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 110
  • TABLE 39 MIDDLE EAST & AFRICA PRIMARY PURE SQUAMOUS CELL CARCINOMA OF THE ENDOMETRIUM IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 111
  • TABLE 40 MIDDLE EAST & AFRICA INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 111
  • TABLE 41 MIDDLE EAST & AFRICA PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 112
  • TABLE 42 MIDDLE EAST & AFRICA UTERINE SARCOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 113
  • TABLE 43 MIDDLE EAST & AFRICA UTERINE SARCOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 114
  • TABLE 44 MIDDLE EAST & AFRICA LEIOMYOSARCOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 114
  • TABLE 45 MIDDLE EAST & AFRICA INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 115
  • TABLE 46 MIDDLE EAST & AFRICA PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 116
  • TABLE 47 MIDDLE EAST & AFRICA ENDOMETRIAL STROMAL SARCOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 117
  • TABLE 48 MIDDLE EAST & AFRICA INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 117
  • TABLE 49 MIDDLE EAST & AFRICA PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 118
  • TABLE 50 MIDDLE EAST & AFRICA UNDIFFERENTIATED SARCOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 119
  • TABLE 51 MIDDLE EAST & AFRICA INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 120
  • TABLE 52 MIDDLE EAST & AFRICA PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 121
  • TABLE 53 MIDDLE EAST & AFRICA UTERINE CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION) 126
  • TABLE 54 MIDDLE EAST & AFRICA >60 YEARS IN UTERINE CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 127
  • TABLE 55 MIDDLE EAST & AFRICA 51-60 YEARS IN UTERINE CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 128
  • TABLE 56 MIDDLE EAST & AFRICA 41-50 YEARS IN UTERINE CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 129
  • TABLE 57 MIDDLE EAST & AFRICA 31-40 YEARS IN UTERINE CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 130
  • TABLE 58 MIDDLE EAST & AFRICA <30 YEARS IN UTERINE CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 131
  • TABLE 59 MIDDLE EAST & AFRICA UTERINE CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 135
  • TABLE 60 MIDDLE EAST & AFRICA HOSPITALS IN UTERINE CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 136
  • TABLE 61 MIDDLE EAST & AFRICA DIAGNOSTIC CENTERS IN UTERINE CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 137
  • TABLE 62 MIDDLE EAST & AFRICA CANCER RESEARCH CENTERS IN UTERINE CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 138
  • TABLE 63 MIDDLE EAST & AFRICA AMBULATORY SURGICAL CENTERS IN UTERINE CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 139
  • TABLE 64 MIDDLE EAST & AFRICA SPECIALIZED CLINICS IN UTERINE CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 140
  • TABLE 65 MIDDLE EAST & AFRICA OTHERS IN UTERINE CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 141
  • TABLE 66 MIDDLE EAST & AFRICA UTERINE CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 145
  • TABLE 67 MIDDLE EAST & AFRICA DIRECT TENDER IN UTERINE CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 146
  • TABLE 68 MIDDLE EAST & AFRICA THIRD PARTY DISTRIBUTORS IN UTERINE CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 147
  • TABLE 69 MIDDLE EAST & AFRICA OTHERS IN UTERINE CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 148
  • TABLE 70 MIDDLE EAST AND AFRICA UTERINE CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2021-2030 (USD MILLION) 154
  • TABLE 71 MIDDLE EAST AND AFRICA UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 154
  • TABLE 72 MIDDLE EAST AND AFRICA INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 154
  • TABLE 73 MIDDLE EAST AND AFRICA ULTRASOUND SCANNING IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 155
  • TABLE 74 MIDDLE EAST AND AFRICA ULTRASOUND SCANNING IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (UNITS) 155
  • TABLE 75 MIDDLE EAST AND AFRICA ULTRASOUND SCANNING IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD) 155
  • TABLE 76 MIDDLE EAST AND AFRICA SYSTEMS IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 155
  • TABLE 77 MIDDLE EAST AND AFRICA SYSTEMS IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (VOLUME) 155
  • TABLE 78 MIDDLE EAST AND AFRICA SYSTEMS IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD) 156
  • TABLE 79 MIDDLE EAST AND AFRICA IMAGING DEVICES IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 156
  • TABLE 80 MIDDLE EAST AND AFRICA IMAGING DEVICES IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (UNITS) 156
  • TABLE 81 MIDDLE EAST AND AFRICA IMAGING DEVICES IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD) 156
  • TABLE 82 MIDDLE EAST AND AFRICA TESTS IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 157
  • TABLE 83 MIDDLE EAST AND AFRICA BLOOD TESTS IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 157
  • TABLE 84 MIDDLE EAST AND AFRICA PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 157
  • TABLE 85 MIDDLE EAST AND AFRICA PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (VOLUME) 157
  • TABLE 86 MIDDLE EAST AND AFRICA PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD) 158
  • TABLE 87 MIDDLE EAST AND AFRICA UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 158
  • TABLE 88 MIDDLE EAST AND AFRICA ENDOMETRIAL CANCER IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 158
  • TABLE 89 MIDDLE EAST AND AFRICA SEROUS ADENOCARCINOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 158
  • TABLE 90 MIDDLE EAST AND AFRICA INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 159
  • TABLE 91 MIDDLE EAST AND AFRICA PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 159
  • TABLE 92 MIDDLE EAST AND AFRICA ADENOSQUAMOUS CARCINOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 159
  • TABLE 93 MIDDLE EAST AND AFRICA INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 159
  • TABLE 94 MIDDLE EAST AND AFRICA PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 160
  • TABLE 95 MIDDLE EAST AND AFRICA UTERINE CARCINOSARCOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 160
  • TABLE 96 MIDDLE EAST AND AFRICA INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 160
  • TABLE 97 MIDDLE EAST AND AFRICA PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 161
  • TABLE 98 MIDDLE EAST AND AFRICA PRIMARY PURE SQUAMOUS CELL CARCINOMA OF THE ENDOMETRIUM IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 161
  • TABLE 99 MIDDLE EAST AND AFRICA INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 161
  • TABLE 100 MIDDLE EAST AND AFRICA PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 162
  • TABLE 101 MIDDLE EAST AND AFRICA UTERINE SARCOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 162
  • TABLE 102 MIDDLE EAST AND AFRICA LEIOMYOSARCOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 162
  • TABLE 103 MIDDLE EAST AND AFRICA INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 163
  • TABLE 104 MIDDLE EAST AND AFRICA PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 163
  • TABLE 105 MIDDLE EAST AND AFRICA ENDOMETRIAL STROMAL SARCOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 163
  • TABLE 106 MIDDLE EAST AND AFRICA INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 164
  • TABLE 107 MIDDLE EAST AND AFRICA PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 164
  • TABLE 108 MIDDLE EAST AND AFRICA UNDIFFERENTIATED SARCOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 164
  • TABLE 109 MIDDLE EAST AND AFRICA INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 164
  • TABLE 110 MIDDLE EAST AND AFRICA PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 165
  • TABLE 111 MIDDLE EAST AND AFRICA UTERINE CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION) 165
  • TABLE 112 MIDDLE EAST AND AFRICA UTERINE CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 165
  • TABLE 113 MIDDLE EAST AND AFRICA UTERINE CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 166
  • TABLE 114 SOUTH AFRICA UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 167
  • TABLE 115 SOUTH AFRICA INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 167
  • TABLE 116 SOUTH AFRICA ULTRASOUND SCANNING IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 167
  • TABLE 117 SOUTH AFRICA ULTRASOUND SCANNING IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (UNITS) 167
  • TABLE 118 SOUTH AFRICA ULTRASOUND SCANNING IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD) 168
  • TABLE 119 SOUTH AFRICA SYSTEMS IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 168
  • TABLE 120 SOUTH AFRICA SYSTEMS IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (VOLUME) 168
  • TABLE 121 SOUTH AFRICA SYSTEMS IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD) 168
  • TABLE 122 SOUTH AFRICA IMAGING DEVICES IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 168
  • TABLE 123 SOUTH AFRICA IMAGING DEVICES IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (UNITS) 169
  • TABLE 124 SOUTH AFRICA IMAGING DEVICES IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD) 169
  • TABLE 125 SOUTH AFRICA TESTS IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 169
  • TABLE 126 SOUTH AFRICA BLOOD TESTS IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 169
  • TABLE 127 SOUTH AFRICA PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 170
  • TABLE 128 SOUTH AFRICA PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (VOLUME) 170
  • TABLE 129 SOUTH AFRICA PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD) 170
  • TABLE 130 SOUTH AFRICA UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 171
  • TABLE 131 SOUTH AFRICA ENDOMETRIAL CANCER IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 171
  • TABLE 132 SOUTH AFRICA SEROUS ADENOCARCINOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 171
  • TABLE 133 SOUTH AFRICA INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 171
  • TABLE 134 SOUTH AFRICA PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 172
  • TABLE 135 SOUTH AFRICA ADENOSQUAMOUS CARCINOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 172
  • TABLE 136 SOUTH AFRICA INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 172
  • TABLE 137 SOUTH AFRICA PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 173

LIST OF FIGURES

  • FIGURE 1 MIDDLE EAST & AFRICA UTERINE CANCER DIAGNOSTIC MARKET: SEGMENTATION 48
  • FIGURE 2 MIDDLE EAST & AFRICA UTERINE CANCER DIAGNOSTIC MARKET: DATA TRIANGULATION 51
  • FIGURE 3 MIDDLE EAST & AFRICA UTERINE CANCER DIAGNOSTIC MARKET: DROC ANALYSIS 52
  • FIGURE 4 MIDDLE EAST & AFRICA UTERINE CANCER DIAGNOSTIC MARKET: MIDDLE EAST & AFRICA VS REGIONAL MARKET ANALYSIS 53
  • FIGURE 5 MIDDLE EAST & AFRICA UTERINE CANCER DIAGNOSTIC MARKET: COMPANY RESEARCH ANALYSIS 53
  • FIGURE 6 MIDDLE EAST & AFRICA UTERINE CANCER DIAGNOSTIC MARKET: INTERVIEW DEMOGRAPHICS 54
  • FIGURE 7 MIDDLE EAST & AFRICA UTERINE CANCER DIAGNOSTIC MARKET: MARKET APPLICATION COVERAGE GRID 56
  • FIGURE 8 MIDDLE EAST & AFRICA UTERINE CANCER DIAGNOSTIC MARKET: DBMR MARKET POSITION GRID 58
  • FIGURE 9 MIDDLE EAST & AFRICA UTERINE CANCER DIAGNOSTIC MARKET: VENDOR SHARE ANALYSIS 60
  • FIGURE 10 MIDDLE EAST & AFRICA UTERINE CANCER DIAGNOSTIC MARKET: SEGMENTATION 64
  • FIGURE 11 GROWING AWARENESS OF UTERINE CANCER AND INCREASING HEALTHCARE EXPENDITURE IS EXPECTED TO DRIVE THE GROWTH OF THE MIDDLE EAST & AFRICA UTERINE CANCER DIAGNOSTIC MARKET FROM 2023 TO 2030 65
  • FIGURE 12 INSTRUMENT BASED SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST & AFRICA UTERINE CANCER DIAGNOSTIC MARKET IN 2023 & 2030 65
  • FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE UTERINE CANCER DIAGNOSTICS MARKET 78
  • FIGURE 14 MIDDLE EAST & AFRICA UTERINE CANCER DIAGNOSTICS MARKET : BY DIAGNOSTIC TYPE, 2022 86
  • FIGURE 15 MIDDLE EAST & AFRICA UTERINE CANCER DIAGNOSTICS MARKET : BY DIAGNOSTIC TYPE, 2023-2030 (USD MILLION) 87
  • FIGURE 16 MIDDLE EAST & AFRICA UTERINE CANCER DIAGNOSTICS MARKET : BY DIAGNOSTIC TYPE, CAGR (2023-2030) 87
  • FIGURE 17 MIDDLE EAST & AFRICA UTERINE CANCER DIAGNOSTICS MARKET : BY DIAGNOSTIC TYPE, LIFELINE CURVE 88
  • FIGURE 18 MIDDLE EAST & AFRICA UTERINE CANCER DIAGNOSTICS MARKET: BY TYPE, 2022 98
  • FIGURE 19 MIDDLE EAST & AFRICA UTERINE CANCER DIAGNOSTICS MARKET: BY TYPE, 2023-2030 (USD MILLION) 99
  • FIGURE 20 MIDDLE EAST & AFRICA UTERINE CANCER DIAGNOSTICS MARKET: BY TYPE, CAGR (2023-2030) 99
  • FIGURE 21 MIDDLE EAST & AFRICA UTERINE CANCER DIAGNOSTICS MARKET: BY TYPE, LIFELINE CURVE 100
  • FIGURE 22 MIDDLE EAST & AFRICA UTERINE CANCER DIAGNOSTICS MARKET: BY AGE GROUP, 2022 123
  • FIGURE 23 MIDDLE EAST & AFRICA UTERINE CANCER DIAGNOSTICS MARKET: BY AGE GROUP, 2023-2030 (USD MILLION) 124
  • FIGURE 24 MIDDLE EAST & AFRICA UTERINE CANCER DIAGNOSTICS MARKET: BY AGE GROUP, CAGR (2023-2030) 124
  • FIGURE 25 MIDDLE EAST & AFRICA UTERINE CANCER DIAGNOSTICS MARKET: BY AGE GROUP, LIFELINE CURVE 125
  • FIGURE 26 MIDDLE EAST & AFRICA UTERINE CANCER DIAGNOSTICS MARKET : BY END USER, 2022 132
  • FIGURE 27 MIDDLE EAST & AFRICA UTERINE CANCER DIAGNOSTICS MARKET : BY END USER, 2023-2030 (USD MILLION) 133
  • FIGURE 28 MIDDLE EAST & AFRICA UTERINE CANCER DIAGNOSTICS MARKET : BY END USER, CAGR (2023-2030) 133
  • FIGURE 29 MIDDLE EAST & AFRICA UTERINE CANCER DIAGNOSTICS MARKET : BY END USER, LIFELINE CURVE 134
  • FIGURE 30 MIDDLE EAST & AFRICA UTERINE CANCER DIAGNOSTICS MARKET : BY DISTRIBUTION CHANNEL, 2022 142
  • FIGURE 31 MIDDLE EAST & AFRICA UTERINE CANCER DIAGNOSTICS MARKET : BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION) 143
  • FIGURE 32 MIDDLE EAST & AFRICA UTERINE CANCER DIAGNOSTICS MARKET : BY DISTRIBUTION CHANNEL, CAGR (2023-2030) 143
  • FIGURE 33 MIDDLE EAST & AFRICA UTERINE CANCER DIAGNOSTICS MARKET : BY DISTRIBUTION CHANNEL, LIFELINE CURVE 144
  • FIGURE 34 MIDDLE EAST AND AFRICA UTERINE CANCER DIAGNOSTICS MARKET: SNAPSHOT (2022) 150
  • FIGURE 35 MIDDLE EAST AND AFRICA UTERINE CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022) 151
  • FIGURE 36 MIDDLE EAST AND AFRICA UTERINE CANCER DIAGNOSTICS MARKET: BY COUNTRY (2023 & 2030) 151
  • FIGURE 37 MIDDLE EAST AND AFRICA UTERINE CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2030) 152
  • FIGURE 38 MIDDLE EAST AND AFRICA UTERINE CANCER DIAGNOSTICS MARKET: BY DIAGNOSTIC TYPE (2023-2030) 152
  • FIGURE 39 MIDDLE EAST & AFRICA UTERINE CANCER DIAGNOSTICS MARKET: COMPANY SHARE 2022 (%) 283
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!